Woburn, MA, Aug. 04, 2025 (GLOBE NEWSWIRE) — Biofrontera Inc., (Nasdaq:BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and six months ended June 30, 2025 on Wednesday, August 13, 2025. The results will be released after the market close on Wednesday, August 13 and the company will host a conference call on Thursday, August 14 at 10:00am Eastern Time.
Conference Call and Webcast Information
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz ® with the RhodoLED ® lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X.
Contacts:
Investor Relations
Andrew Barwicki
1-516-662-9461
[email protected]
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.